Drugs / POLZASTOBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04669899 | Jan 2021 → Nov 2023 | cancer | Jounce Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POLZASTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095353 ↗ |
| Known as | JTX-8064 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04669899 ↗ |
| Action | Inhibit | “designed to block the interaction of LILRB2” NCT04669899 ↗ |
| Modality | Monoclonal antibody | “JTX-8064 is a humanized mAb” NCT04669899 ↗ |
| Target | LILRB2 | “block the interaction of LILRB2” NCT04669899 ↗ |